Immune cell function test for people on immunotherapy
Part of Cancer, Immune system & allergy clinical trials.
This study is for people with advanced solid tumors who are about to start immunotherapy, either alone or with chemotherapy. It involves a blood test to check how your immune cells are working, which may help doctors understand how well the treatment is working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older with a confirmed solid tumor that has spread or is advanced.
- You are about to start immunotherapy (like anti-PD1, anti-PDL1, or anti-CTLA4) either alone or with chemotherapy.
- You have not had chemotherapy in the 3 weeks before your first immunotherapy dose.
- You are not getting immunotherapy together with a targeted therapy drug.
- You do not have another cancer that is growing or needs treatment right now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for early “predictive clues” (often blood or test markers) that can forecast immune-related side effects in people treated with immune checkpoint medicines. The goal is to help doctors recognize who may be more likely to have these side effects while receiving treatment.
This study is testing a blood test (Episwitch CiRT®) that looks at your DNA to see if it can predict whether you will respond to a type of immunotherapy called PD-(L)-1 checkpoint inhibitors. The goal is to see if this test is accurate across many different types of cancer.
This study collects blood and tumor samples to understand how well cancer immunotherapy works and what side effects may happen. It mainly helps researchers by checking “immune markers” before treatment starts, while you receive planned immune checkpoint therapy.
This study follows people who are starting their first immune “checkpoint” treatment for a solid cancer. It collects clinic information and lab results to understand how patients respond and what factors matter most.
This study looks at how your body reacts to immunotherapy drugs (like PD-1 or CTLA-4 blockers) when given for the first time. It aims to predict side effects and help make treatment safer.
This study looks at how people’s bodies respond to cancer immunotherapy and why some people get side effects. Your information and lab results may help improve how immunotherapy is managed in the future.
Hear when a new Immunotherapy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.